Aclaris Therapeutics (ACRS) Retained Earnings (2017 - 2025)
Historic Retained Earnings for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to -$948.0 million.
- Aclaris Therapeutics' Retained Earnings fell 1757.28% to -$948.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$948.0 million, marking a year-over-year decrease of 1757.28%. This contributed to the annual value of -$902.9 million for FY2024, which is 1713.36% down from last year.
- Aclaris Therapeutics' Retained Earnings amounted to -$948.0 million in Q3 2025, which was down 1757.28% from -$933.4 million recorded in Q2 2025.
- Over the past 5 years, Aclaris Therapeutics' Retained Earnings peaked at -$533.3 million during Q1 2021, and registered a low of -$948.0 million during Q3 2025.
- For the 5-year period, Aclaris Therapeutics' Retained Earnings averaged around -$732.9 million, with its median value being -$740.0 million (2023).
- Its Retained Earnings has fluctuated over the past 5 years, first crashed by 1800.94% in 2021, then tumbled by 481.01% in 2024.
- Quarter analysis of 5 years shows Aclaris Therapeutics' Retained Earnings stood at -$595.4 million in 2021, then dropped by 14.6% to -$682.3 million in 2022, then fell by 12.97% to -$770.8 million in 2023, then decreased by 17.13% to -$902.9 million in 2024, then dropped by 5.0% to -$948.0 million in 2025.
- Its last three reported values are -$948.0 million in Q3 2025, -$933.4 million for Q2 2025, and -$917.9 million during Q1 2025.